Report Content

Chapter 1   Methodology & Scope

1.1    Definitions and forecast parameters

1.1.1    Definitions

1.1.2    Methodology and forecast parameters

1.2    Data sources

1.2.1    Secondary

1.2.2    Primary

Chapter 2   Executive Summary

2.1    North America bioreactors industry summary, 2017-2028

2.1.1    Country trends

2.1.2    Product type trends

2.1.3    Cell trends

2.1.4    Molecule trends

2.1.5    Usage trends

2.1.6    End-user trends

Chapter 3   Industry Insights

3.1    Industry segmentation

3.2    Industry landscape, 2017-2028 (USD Million)

3.3    Major factor analysis

3.3.1    Drivers

3.3.1.1   Growing pharmaceutical and biotechnology industry in the region

3.3.1.2   Rising government initiatives in the region

3.3.1.3   Technological advancements in bioprocessing systems

3.3.1.4   Rising demand for vaccines and cell-targeted therapies

3.3.2    Industry pitfalls and challenges

3.3.2.1   Limitations associated with single-use bioreactors

3.3.2.2   Concerns regarding extractables and leachables

3.3.2.3   Stringent regulatory framework

3.4    Analysis of COVID-19 impact on the industry

3.5    Porter’s analysis

3.6    Competition review, 2021

3.7    PEST analysis

Chapter 4   North America Bioreactors Market, By Product Type

4.1    Market trends

4.2    Single use

4.2.1    Market estimates and forecast, by country, 2017-2028 (USD Million)

4.3    Reusable

4.3.1    Market estimates and forecast, by country, 2017-2028 (USD Million)

Chapter 5   North America Bioreactors Market, By Cell

5.1    Market trends

5.2    Mammalian cells

5.2.1    Market estimates and forecast, by country, 2017-2028 (USD Million)

5.3    Bacterial cells

5.3.1    Market estimates and forecast, by country, 2017-2028 (USD Million)

5.4    Yeast cells

5.4.1    Market estimates and forecast, by country, 2017-2028 (USD Million)

5.5    Others

5.5.1    Market estimates and forecast, by country, 2017-2028 (USD Million)

Chapter 6   North America Bioreactors Market, By Molecule

6.1    Market trends

6.2    Monoclonal antibodies

6.2.1    Market estimates and forecast, by country, 2017-2028 (USD Million)

6.3    Vaccines

6.3.1    Market estimates and forecast, by country, 2017-2028 (USD Million)

6.4    Recombinant proteins

6.4.1    Market estimates and forecast, by country, 2017-2028 (USD Million)

6.5    Stem cells

6.5.1    Market estimates and forecast, by country, 2017-2028 (USD Million)

6.6    Gene therapy

6.6.1    Market estimates and forecast, by country, 2017-2028 (USD Million)

6.7    Others

6.7.1    Market estimates and forecast, by country, 2017-2028 (USD Million)

Chapter 7   North America Bioreactors Market, By Usage

7.1    Market trends

7.2    Developmental, pre-clinical & clinical

7.2.1    Market estimates and forecast, by country, 2017-2028 (USD Million)

7.3    Commercial production

7.3.1    Market estimates and forecast, by country, 2017-2028 (USD Million)

Chapter 8   North America Bioreactors Market, By End-user

8.1    Market trends

8.2    R&D organizations

8.2.1    Market estimates and forecast, by country, 2017-2028 (USD Million)

8.3    Biopharma manufacturers

8.3.1    Market estimates and forecast, by country, 2017-2028 (USD Million)

8.4    Contract manufacturing organizations (CMOs)

8.4.1    Market estimates and forecast, by country, 2017-2028 (USD Million)

Chapter 9   North America Bioreactors Market, By Country

9.1    Market trends

9.2    U.S.

9.2.1    Market estimates and forecast, by product type, 2017-2028 (USD Million)

9.2.2    Market estimates and forecast, by cell, 2017-2028 (USD Million)

9.2.3    Market estimates and forecast, by molecule, 2017-2028 (USD Million)

9.2.4    Market estimates and forecast, by usage, 2017-2028 (USD Million)

9.2.5    Market estimates and forecast, by end-user, 2017-2028 (USD Million)

9.3    Canada

9.3.1    Market estimates and forecast, by product type, 2017-2028 (USD Million)

9.3.2    Market estimates and forecast, by cell, 2017-2028 (USD Million)

9.3.3    Market estimates and forecast, by molecule, 2017-2028 (USD Million)

9.3.4    Market estimates and forecast, by usage, 2017-2028 (USD Million)

9.3.5    Market estimates and forecast, by end-user, 2017-2028 (USD Million)

Chapter 10   Company Profiles

10.1    Applikon Biotechnology, Inc. (Getinge)

10.1.1    Business overview

10.1.2    Financial data

10.1.3    Product landscape

10.1.4    Strategic outlook

10.2    Bbi-biotech

10.2.1    Business overview

10.2.2    Financial data

10.2.3    Product landscape

10.2.4    Strategic outlook

10.3    Cellexus Limited

10.3.1    Business overview

10.3.2    Financial data

10.3.3    Product landscape

10.3.4    Strategic outlook

10.4    CerCell Aps

10.4.1    Business overview

10.4.2    Financial data

10.4.3    Product landscape

10.4.4    Strategic outlook

10.5    Eppendorf AG

10.5.1    Business overview

10.5.2    Financial data

10.5.3    Product landscape

10.5.4    Strategic outlook

10.6    Cytiva (Danaher Corporation)

10.6.1    Business overview

10.6.2    Financial data

10.6.3    Product landscape

10.6.4    Strategic outlook

10.7    GEA Group Aktiengesellschaft

10.7.1    Business overview

10.7.2    Financial data

10.7.3    Product landscape

10.7.4    Strategic outlook

10.8    Merck Group

10.8.1    Business overview

10.8.2    Financial data

10.8.3    Product landscape

10.8.4    Strategic outlook

10.9    Pierre Guerin SAS

10.9.1    Business overview

10.9.2    Financial data

10.9.3    Product landscape

10.9.4    Strategic outlook

10.10    Sartorius Stedim Biotech Group

10.10.1    Business overview

10.10.2    Financial data

10.10.3    Product landscape

10.10.4    Strategic outlook

10.11    Solaris Biotech Solutions

10.11.1    Business overview

10.11.2    Financial data

10.11.3    Product landscape

10.11.4    Strategic outlook

10.12    Thermo Fisher Scientific Inc.

10.12.1    Business overview

10.12.2    Financial data

10.12.3    Product landscape

10.12.4    Strategic outlook

10.13    Solida Biotech

10.13.1    Business overview

10.13.2    Financial data

10.13.3    Product landscape

10.13.4    Strategic outlook